Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TC A101

Next Previous
Drug Profile

TC A101

Alternative Names: anti-ALPP CAR-T cells - TCRCure Biopharma; CARs-T therapy - TCRCure Biotech; Retroviral vector-transduced anti-ALPP CARs-T therapy - TCRCure Biotech; TC-A101

Latest Information Update: 30 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TCRCure Biopharma
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Endometrial cancer; Solid tumours

Most Recent Events

  • 27 Mar 2023 Discontinued - Phase-I/II for Endometrial cancer (Late-stage disease) in China (Parenteral) prior to March 2023 (TCRCure Biopharma website, March 2023)
  • 27 Mar 2023 Discontinued - Phase-I/II for Ovarian cancer (Late-stage disease) in China (Parenteral) prior to March 2023 (TCRCure Biopharma website, March 2023)
  • 09 Sep 2022 Efficacy and adverse event data from a phase I/II trial in Ovarian cancer and Endometrial cancers presented at the 47th European Society for Medical Oncology Congress (ESMO-2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top